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What is the key question? 
For treatment of acute pulmonary embolism (PE), the benefits and risks of the 
different recanalization procedures (i.e., full-dose systemic thrombolysis, 
reduced-dose systemic thrombolysis, or catheter-directed thrombolysis) vs. 
each other lack clarity. 
 
What is the bottom line? 
Compared with standard anticoagulation, recanalization procedures had a 
similar risk of all-cause mortality, and full-dose thrombolysis was associated 
with an increased risk of major bleeding. 
 
Why read on? 
Low-dose thrombolysis was associated with the lowest probability of dying and 
bleeding.  





Background: We aimed to review the efficacy and safety of recanalization 
procedures for the treatment of pulmonary embolism (PE). 
 
Methods: We searched PubMed, the Cochrane Library, EMBASE, EBSCO, 
Web of Science, and CINAHL databases from inception through July 31, 2015, 
and included randomized clinical trials that compared the effect of a 
recanalization procedure vs. each other or anticoagulant therapy in patients 
diagnosed with PE. We used network meta-analysis and multivariate random-
effects meta-regression to estimate pooled differences between each 
intervention, and meta-regression to assess the association between trial 
characteristics and the reported effects of recanalization procedures vs. 
anticoagulation. 
 
Results: For all-cause mortality, there were no significant differences in event 
rates between any of the recanalization procedures and anticoagulant treatment 
(full-dose thrombolysis: odds ratio, 0.60; 95% confidence interval [CI], 0.36-
1.01; low-dose thrombolysis: 0.47; 95% CI, 0.14-1.59; and catheter-associated 
thrombolysis: 0.31; 95% CI, 0.01-7.96). Full-dose thrombolysis increased the 
risk of major bleeding (2.00; 95% CI, 1.06-3.78) compared with anticoagulation. 
Catheter-directed thrombolysis was associated with the lowest probability of 
dying (surface under the cumulative ranking curve [SUCRA], 0.67), followed by 
low-dose thrombolysis (SUCRA, 0.66), and full-dose thrombolysis (SUCRA, 
0.55). Similarly, low-dose thrombolysis was associated with the lowest 
probability of major bleeding (SUCRA, 0.61), followed by catheter-directed 
thrombolysis (SUCRA, 0.54), and full-dose thrombolysis (SUCRA, 0.17). The 
results were similar in sensitivity analyses based on restricting only to studies in 
hemodynamically stable PE patients. 
 
Conclusions: In the treatment of PE, recanalization procedures do not seem to 
offer a clear advantage compared with standard anticoagulation. Low-dose 
thrombolysis was associated with the lowest probability of dying and bleeding. 
 




Trial registration: PROSPERO CRD42015024670. 
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Although most patients with acute pulmonary embolism (PE) have an 
uncomplicated clinical course while undergoing standard anticoagulation 
treatment, the overall short-term mortality rate is still significant (1, 2). Death 
from acute PE usually occurs before or soon after hospital admission (3, 4). 
 
There have been two main treatments for acute PE, anticoagulant therapy 
alone or systemic thrombolytic therapy (5). Most patients presenting to the 
hospital with PE have normal blood pressure, normal right ventricular function, 
and a low clinical severity score and therefore have a very low short-term 
mortality with prompt initiation of anticoagulation. Although systemic 
thrombolysis has angiographic and haemodynamic benefits for patients with 
acute PE, compared to standard therapy, it markedly increases major bleeding, 
including intracranial and fatal bleeding (6). Consequently, systemic 
thrombolytic therapy is usually reserved for PE patients with hemodynamic 
instability (7). The ability to actively remove emboli in patients with acute PE 
without increasing bleeding would be an important advance. Low-dose systemic 
thrombolysis and catheter-based thrombolytic therapy require only a fraction of 
the systemic fibrinolytic dose, and this dose reduction might improve the safety 
of thrombolysis for PE. A common problem in evaluating the efficacy of these 
interventions is the lack of trials (or a paucity of available trials) that directly 
compare these interventions. As a result, no meta-analysis has 
comprehensively compared the effect of a recanalization procedure vs. each 
other in patients diagnosed with acute symptomatic PE.  
 
The primary aim of our study was to perform a network meta-analysis of 
randomised controlled trials (RCT) for treatment of acute PE to obtain a better 
estimate of the benefits and risks of the different recanalization procedures (i.e., 
full-dose systemic thrombolysis, reduced-dose systemic thrombolysis, or 








Data sources and searches 
This systematic review is reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
statement extension for network meta-analysis and was conducted following an 
a priori–established protocol registered with PROSPERO (8). We searched 
PubMed, the Cochrane Library, EMBASE, EBSCO, Web of Science, and 
CINAHL databases. Each database was searched from its inception date to 31 
July 2015. Conference abstracts were included in our search. The retrieved 
articles were examined to eliminate potential duplicates or overlapping data. No 
limits or language restriction were applied during the search. The RCTs were 
identified using the Cochrane Collaboration highly sensitive search strategy 
(sensitivity-maximizing and precision-maximizing version) (9). The search string 
was: #1. pulmonary embolis*; #2. thrombolysis OR thrombolytic therapy OR 
streptokinase OR urokinase OR tenecteplase OR alteplase OR desmoteplase 
OR tissue plasminogen activator OR clot-dissolving medication; #3. #1 AND #2. 
We also hand searched the references of relevant articles for additional clinical 
trials not identified by the electronic search and contacted experts. Finally we 
searched clinicaltrials.gov for information on clinical trials that were terminated 
but unpublished. The planned analysis was registered at the PROSPERO 




One reviewer (DJ) performed the database search and initial screening of titles 
and abstracts. Two investigators (DJ, RM) independently carried out full text 
screening of all eligible articles. We included a study if participants were 
patients with acute symptomatic PE objectively diagnosed with standard 
imaging techniques and received anticoagulant therapy; the intervention was 
treatment with a recanalization procedure (i.e., full-dose systemic thrombolysis, 
reduced-dose systemic thrombolysis, or catheter-directed thrombolysis); the 
comparison group was either treatment with a different recanalization procedure 
or no recanalization treatment (i.e., the patients received standard 
anticoagulation); it was a randomised controlled trial; and it reported mortality 
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outcomes. Observational studies, and trials without a control group were 
excluded. 
 
Data extraction and quality assessment 
Two reviewers (DJ and RM) independently extracted data onto a computer 
spreadsheet, with discrepancies resolved by consensus. Extracted data 
included first author, year of publication, type of intervention and control group, 
number of patients, patient characteristics, and duration of follow-up. The 
primary outcomes were all-cause mortality and major bleeding, as defined by 
the study protocol. Secondary outcomes were risk of intracranial hemorrhage 
(ICH) and recurrent embolism. The occurrence of these outcomes was 
abstracted according to the intention-to-treat population for individual trials. The 
outcomes data from the first available time point identified as a primary end 
point from each trial were incorporated into our primary analysis. Each study 
was graded for potential bias into low, high, and unclear according to the 
Cochrane Collaboration handbook (10). 
 
Data synthesis and analysis 
Separate meta-analyses of direct evidence only (pairwise meta-analyses) were 
performed using DerSimonian and Laird random-effects model to estimate 
pooled odds ratios (ORs) and 95% confidence intervals (CIs) (11). Forest plots 
were created for each outcome. When there were no events in one treatment 
group, we used a 0.5 continuity correction. Heterogeneity was assessed using 
the estimated between-study variance (τ2), Cochran χ2 test, and the I2 statistic 
(12). 
 
Because there are few trials making head to head comparisons between 
recanalization procedures, we performed a network metaanalysis. Unlike 
traditional meta-analyses, this method has the advantage of allowing trials 
comparing recanalization procedures with some other common treatment (e.g., 
placebo) to be incorporated into the analysis, thus increasing power and 
enabling a better comparison of recanalization therapies to be made (13). We 
used multivariate, random-effects meta-regressions to perform each analysis 
using the network family of commands in Stata (14). We evaluated 
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inconsistency between direct and indirect sources of evidence by comparison of 
the fit and parsimony of consistency and inconsistency models and by 
calculation of the difference between direct and indirect estimates of a specific 
treatment effect (‘loop-specific approach’). The relative ranking of recanalization 
interventions on primary and secondary outcomes was presented as their 
surface under the cumulative ranking (SUCRA) probabilities, which represent 
their likelihood of being ranked best (15). In this study, higher SUCRA scores 
reflect lower associated all-cause mortality and bleeding events. We estimated 
the probability of each treatment being the best by averaging 10,000 Monte 
Carlo replications. The level of statistical significance was set at P < 0.05 and all 
statistical tests were 2-sided. 
 
We performed some sensitivity analyses to assess the robustness of the 
findings. These were based on (1) restricting only to studies in patients with 
hemodynamically stable PE; (2) restricting only to trials where the mean age of 
participants in the thrombolytic group was > 65 years; and (3) alternative 






From a total of 930 unique studies identified using the search strategy, 22 RCTs 
(2,494 patients) were included in the network meta-analysis (eFigure 1). These 
included 16 trials comparing full-dose thrombolysis to no thrombolysis (2,016 
patients) (6, 16-30), 1 comparing low-dose thrombolysis to no thrombolysis  
(121 patients) (31), 1 comparing ultrasound-assisted catheter-directed 
thrombolysis with no thrombolysis (59 patients) (32), and 4 comparing full-dose 
thrombolysis with low-dose thrombolysis (298 patients) (33-36). The available 
direct comparisons and network of trials is shown in Figure 1 and eFigures 2-4 
in the Supplement. 
 
Characteristics of included studies 
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The RCTs included in the network meta-analysis are summarized in Table 1. 
Overall, these 22 trials were reported between 1970 and 2014 and included 
2,494 participants. The mean study sample size was 113 participants, ranging 
from 8 to 1,005 patients. The baseline characteristics of patients included in 
these trials are described in Table 1. The primary outcome (all-cause mortality) 
was reported in all studies. 
 
Direct meta-analysis 
Results of direct pairwise meta-analysis are summarized in Table 2 and 
eFigures 5-8 in the Supplement. All interventions were associated with a 
nonsignificant reduction of all-cause mortality (full-dose thrombolysis: odds ratio 
[OR], 0.64; 95% CI, 0.37 to 1.09; low-dose thrombolysis: 0.32, 0.03 to 3.13; 
catheter-directed thrombolysis: 0.31, 0.01 to 7.96); full-dose thrombolysis was 
not superior to low-dose thrombolysis (1.04, 0.24 to 4.41). Full-dose 
thrombolytic therapy was significantly associated with a greater risk of major 
bleeding (2.39, 1.44 to 3.95) and intracranial haemorrhage (ICH) (3.66, 1.13 to 
11.86) compared with anticoagulant therapy (eFigures 6 and 7 in the 
Supplement), whereas low-dose thrombolysis showed a nonsignificant benefit 
in terms of major bleeding and ICH compared with full-dose thrombolysis (Table 
2). All outcomes were associated with negligible heterogeneity (I2 < 12%). 
 
Network meta-analysis –primary outcomes 
In network meta-analysis, compared with anticoagulation alone, full-dose 
thrombolysis was associated with an OR of 0.60 (95% CI, 0.36-1.01), low-dose 
thrombolysis with an OR of 0.47 (95% CI, 0.14-1.59), and catheter-directed 
thrombolysis with an OR of 0.31 (95% CI, 0.01-7.96) for dying (Figure 2). When 
recanalization treatments were compared, none of comparisons reached 
conventional level of statistical significance (Figure 2). In network meta-
analysis, compared with anticoagulation alone, full-dose thrombolysis was 
associated with an OR of 2.00 (95% CI, 1.06-3.78), low-dose thrombolysis with 
an OR of 0.90 (95% CI, 0.25-3.21), and catheter-directed thrombolysis with an 
OR of 0.97 (95% CI, 0.02-56.03) for bleeding (Figure 2). Again, when 
recanalization treatments were compared for bleeding, none of comparisons 
reached conventional level of statistical significance (Figure 2). 




Network meta-analysis suggested that catheter-directed thrombolysis was 
associated with the lowest probability of dying (SUCRA, 0.67), followed by low-
dose thrombolysis (SUCRA, 0.66), and full-dose thrombolysis (SUCRA, 0.55) 
(Figure 3). Similarly, low-dose thrombolysis was associated with the lowest 
probability of major bleeding (SUCRA, 0.61), followed by catheter-directed 
thrombolysis (SUCRA, 0.54), and full-dose thrombolysis (SUCRA, 0.17) (Figure 
3). 
 
Network meta-analysis –secondary outcomes 
In network meta-analysis, compared with anticoagulation, all procedures had 
0.48 to 2.07 odds of being associated with ICH (eFigure 9). Compared with 
anticoagulant therapy, low-dose thrombolysis was associated with the lowest 
odds of ICH (OR, 0.48; 95% CI, 0.07-3.14; SUCRA, 0.78), whereas full-dose 
thrombolysis (OR, 2.07; 95% CI, 0.86-5.02; SUCRA, 0.16) was associated with 
the highest odds of ICH (eFigure 10). 
 
Compared with anticoagulation, all procedures had 0.34 to 0.97 lower odds of 
being associated with recurrent embolism (eFigure 9). Compared with 
anticoagulant therapy, low-dose thrombolysis was associated with the lowest 
odds of recurrent embolism (OR, 0.34; 95% CI, 0.09-1.25; SUCRA, 0.81), 
whereas catheter-directed thrombolysis (OR, 0.97; 95% CI, 0.02-50.36; 




Results from sensitivity analyses are reported in eTable 1 in the Supplement. 
Overall, the results were similar to the main analysis for the primary outcome in 
sensitivity analyses based on (1) restricting only to studies in patients with 
hemodynamically stable PE; (2) restricting only to trials where the mean age of 
participants in the thrombolytic group was > 65 years; and (3) alternative 
statistical model (frequentist approach using a random-effects inconsistency 
model). 
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Publication bias and network consistency 
There was no evidence of publication bias, either qualitatively based on funnel-
plot asymmetry (eFigure 11 in the Supplement) or quantitatively (Egger 
regression test, P > 0.05 for all comparisons), although the number of studies 
included in each comparison was small. There were significant differences 
between direct and indirect estimates in the only closed loop that allowed 
assessment of network consistency (anticoagulation-full-dose thrombolysis-low-
dose thrombolysis).  
 
Quality of evidence 
The risk of bias summary and figure for included studies are listed in eFigure 
12 and eTable 2 in the Supplement. Some studies did not present details for 
randomization, allocation concealment, and blinding. No more than 4 of the 
included trials (< 20%) were deemed to be at high risk of bias in only 3 domains 
(randomization, allocation concealment, blinding) of the Cochrane Collaboration 
risk of bias tool. In most domains, the majority of trials were at low risk, except 
for the allocation concealment and blinding categories in which most trials were 





To our knowledge, this is the first network meta-analysis comparing full-dose 
thrombolysis, low-dose thrombolysis, catheter-directed thrombolysis and 
inactive controls on mortality and other adverse outcomes in patients with acute 
symptomatic PE. The study has several key findings. First, full-dose 
thrombolysis, low-dose thrombolysis, and catheter-directed thrombolysis 
showed a non-significant trend toward lower risk of all-cause death compared 
with anticoagulation. Second, full-dose thrombolysis was associated with higher 
odds of major bleeding compared with anticoagulant treatment, with moderate 
confidence in estimates, but was associated with lower odds of recurrences. 
Third, low-dose thrombolysis was the treatment that performed best in terms of 
efficacy (all-cause mortality) and safety (major bleeding). However, the clinical 
interpretation of these findings is limited not only by the uncertainty around 
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these estimates, but also by the potential bias due to the small number of trials 
in each node. 
 
Traditional pairwise meta-analyses are limited in helping to summarise the most 
effective treatment among different kinds of recanalization procedures. Other 
than comparisons between full-dose thrombolysis and anticoagulant therapy 
(37, 38), the number of studies that analysed each particular pair of treatments 
is still relatively small. Furthermore, for some procedures (i.e., full-dose vs. 
catheter-directed thrombolysis) there was no direct comparative research. The 
ability to estimate effectiveness in this work using network meta-analysis allows 
for more comprehensive assessment of treatment options than has been 
previously possible. Additionally, in contrast to separate pairwise analyses, we 
have been able to rank each treatment based on the strength of its association 
with mortality and bleeding. Even though the results of the pairwise and network 
meta-analyses were mostly similar, the biggest difference was seen in the 
comparison of full-dose with anticoagulation on intracranial haemorrhage with 
the pairwise meta-analysis estimating a larger association than the network 
model. This was most likely because to the large amount of between-study 
variation observed in the indirect comparisons being incorporated into the 
analysis. 
 
Some previous pairwise meta-analyses showed significantly lower associated 
mortality with full-dose systemic thrombolytic use in PE (37, 38). In our study, 
we did not find a significant reduction in all-cause mortality with full-dose 
thrombolytic therapy. This discrepancy between the studies may be explained 
at least in part by the use of different methodological and statistical techniques. 
For low-dose systemic thrombolysis and catheter-directed thrombolysis, lack of 
statistical power might account for the nonsignificant results, as suggested by 
the wider confidence intervals. Alternatively, full-dose systemic thrombolysis 
showed a significant association with major bleeding, a finding consistent with 
previous meta-analyses (37-39). While low-dose and catheter-directed 
thrombolysis have the potential to offer benefits of full-dose systemic 
thrombolysis while minimizing bleeding risk attributable to a lower dose of the 
thrombolytic agent, limited randomized clinical trial data might be the main 
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obstacle for providing a definitive conclusion on the comparison of the effect of 
different reperfusion therapies on major bleeding and ICH. On balance, our 
results show that low-dose and catheter-directed thrombolysis seem the most 
highly ranked treatment across the two primary outcomes. Since catheter-
directed thrombolysis requires rapid access to the cardiac catheterization or 
interventional radiology laboratory (5), low-dose thrombolysis is appealing for 
PE patients when early recanalization procedures are indicated. However, it 
should be kept in mind that in patients with such presentations, particularly 
when PE is associated with hemodynamic instability, there are relatively few 
data for any approaches other than standard-dose systemic thrombolysis. 
 
Ultimately, given the differences in safety, efficacy, and response to therapy, 
from a clinical perspective, the clinician should always consider the overall 
clinical picture, and patient management plans need to balance the risks and 
benefits. There is also a need for randomized trials that compare low-dose 
thrombolytic therapy in with anticoagulation alone in stable patients who have 
intermediate-high risk PE. Evidence from such studies would place the role of 
this procedure for PE on a firmer footing. 
 
This study has limitations. First, there was a paucity of head-to-head trials. 
Second, the biggest threat to validity of the results of any meta-analysis is 
conceptual heterogeneity (i.e., considerable differences among trials in patient 
characteristics, studied interventions, outcome assessment, or study design), 
which can limit the comparability of trials. Strategies to limit the effect of 
conceptual heterogeneity included strict inclusion and exclusion criteria and the 
use of various sensitivity analyses to assess the robustness of the results. 
Third, we found inconsistency for efficacy, which was mainly determined by the 
loop of anticoagulation-full-dose thrombolysis-low-dose thrombolysis. Since 
some evidence suggests that quality of thrombolytic clinical trials has 
substantially changed in the past 30 years, we believe that this inconsistency 
might be a consequence of a cohort effect that relates to different methods used 
in the older studies compared with those done more recently (40). Fourth, 
ranking probabilities may be affected by unequal numbers of trials per 
comparison, sample size of individual studies, network configuration, and effect 
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sizes among treatments and should be interpreted with caution. Finally, some 
included trials had an unclear or high rate of selection and performance bias, 
and there are unaddressed concerns regarding the effect of recanalization 
procedures in a clinical setting. 
 
In conclusion, compared with standard anticoagulation, recanalization 
procedures had a similar risk of all-cause mortality, though full-dose 
thrombolysis was associated with an increased risk of major bleeding. This 
network metaanalysis did not identify a statistically significant difference 
between the outcomes associated with these therapies, but low-dose 
thrombolysis was associated with the lowest probability of dying and bleeding. 
The current body of evidence is limited and further conclusive studies are 
needed to establish the role of each of the recanalization procedures. 
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Figure 1. Network of included studies with available direct comparisons for 
all-cause mortality 
 
Figure 2. Network meta-analysis estimates of all-cause mortality (upper 
triangle) and major bleeding (lower triangle) for each comparison 
 
Figure 3. Clustered ranking plot based on cluster analysis of surface under 
the cumulative ranking curve (SUCRA) for benefit (all-cause mortality) and 
safety (major bleeding). Treatments lying in the upper right corner are more 
effective and safe than the other treatments 
 
eFigure 1. Study identification and selection 
 
eFigure 2. Network of included studies with available direct comparisons 
for major bleeding 
 
eFigure 3. Network of included studies with available direct comparisons 
for intracranial haemorrhage 
 
eFigure 4. Network of included studies with available direct comparisons 
for recurrent venous thromboembolism 
 
eFigure 5. Odds of mortality in patients with pulmonary embolism treated 
with different recanalization procedures 
 
eFigure 6. Odds of major bleeding in patients with pulmonary embolism 
treated with different recanalization procedures 
 
eFigure 7. Odds of intracranial haemorrhage in patients with pulmonary 
embolism treated with different recanalization procedures 
 
eFigure 8. Odds of recurrent venous thromboembolism in patients with 
pulmonary embolism treated with different recanalization procedures 
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eFigure 9. Network meta-analysis estimates of recurrent venous 
thromboembolism (upper triangle) and intracranial haemorrhage (lower 
triangle) for each comparison 
 
eFigure 10. Clustered ranking plot based on cluster analysis of surface 
under the cumulative ranking curve (SUCRA) for benefit (recurrent venous 
thromboembolism) and safety (intracranial haemorrhage). Treatments lying 
in the upper right corner are more effective and safe than the other 
treatments 
 
eFigure 11. Publication bias assessed via funnel plots assessed for the 
primary outcomes. 
 
eFigure 12. Quality assessment of 22 RCTs included in the analysis 




Table 1. Characteristics of included randomized clinical trials 
 
Source Number of 
patients 




Mean (range or 
SD), y 












Placebo No 66.2 (15.3) 30 473 
(47%) 
Yes Yes Yes Yes 
Kline et al (16), 
2014 
83 Tenecteplase Placebo No 55.4 (14) 5 49 
(59.0) 
Yes Yes Yes Yes 




Placebo No 68.1 (1.9) 7 13 
(22.4) 
Yes Yes Yes Yes 
Konstantinides 
et al (18), 2002 
256 Alteplase 
(100 mg) 
Placebo No 62.1 (10.5) 30 122 
(47.6) 
Yes Yes Yes Yes 




Placebo No 58.5 (17) 14 44 
(44.0) 
Yes Yes Yes Yes 
Dalla-Volta et 
al (20), 1992 
36 Alteplase 
(100 mg) 
Placebo No 64.7 (12.5) 30 12 
(33.0) 
Yes Yes Yes Yes 
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Levine et al 
(21), 1990 
58 Alteplase 
(0.6 mg/Kg of 
ideal body 
weight) 
Placebo No 61.5 (2.7) 10 29 
(54.5) 
Yes Yes Yes Yes 




Placebo No 58.5 (15.8) 7 9 
(55.6) 
Yes Yes Yes No 
Marini et al 
(23), 1988 
30 Urokinase 
(800 000 IU for 
12h/d for 3d or 
3 300 000 IU 
for 12h) 
Placebo No 53 (23-72)  11 
(44) 
Yes Yes Yes Yes 
Ly et al (24), 
1978 
25 Streptokinase 
(250 000 IU 
loading dose, 
then 100 000 
IU/h for 72h) 
Placebo Yes 53.2 (23-70) 10 11 
(44.0) 
Yes Yes No No 
Tibbutt et al 
(25), 1974 
30 Streptokinase 





100 000U/h IV 
for 72h) 
Placebo Yes 48.7 (25-71) 3 15 
(50.0) 




(2 000 U/lb, 
then 2 000 
U/lb/h for 12h) 
Placebo Yes b 14 92 
(57.3) 
Yes Yes Yes Yes 




Placebo No 56.0 (16.1) 180 41 
(56.9) 
Yes Yes Yes Yes 
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Jerjes et al 
(28), 1995 
8 Streptokinase 
(1 500 000 IU) 
Placebo Yes 51 (22.9) 1-3 5 
(63.0) 
Yes Yes Yes No 
Dotter et al 
(29), 1979 
31 Streptokinse 
(2 000 000 to 
11 000 000 IU) 
Placebo Yes Yes 14 c Yes Yes Yes Yes 
Taherkahni et 





(1 500 000 IU) 
Placebo No 55.7 (12.4) 7 20 
(40.0) 
Yes Yes Yes No 




Placebo No Intervention: 58 (9) 
Control: 59 (10) 
840 55 
(45.5) 
Yes Yes Yes Yes 
Kucher et al 
(32), 2014 
59 rt-PA 
(10 to 20 mg 
through PA 
catheter) 
Placebo No 63 (14) 90 28 
(47.5) 
Yes Yes Yes Yes 








of 50 mg) 
Yes Intervention: 53 
(17) 
Control: 58 (16) 
14 46 
(51.1) 
Yes Yes Yes Yes 








of 50 mg) 
Yes Intervention: 69 
(12) 
Control: 67 (17) 
Hospital stay 23 
(43.4) 
Yes Yes Yes Yes 












Yes Yes Yes Yes 




al (36), 2011 
40 Streptokinase 
(1 000 000 IU 
over 1 hour) 
Streptokinase 
(250 000 IU 
over 30 min, 
then 100 000 
IU/h over 24 h) 
No NA  NA Yes Yes No No 
 
a Patients also received standard anticoagulation. 




Abbreviations: PE, pulmonary embolism; ICH, intracraneal haemorrhage; VTE, venous thromboembolism; rt-PA, recombinant tissue plasminogen activator; 
IU, international units.  
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Table 2. Summary of direct meta-analysis for all-cause mortality and 
adverse event outcomes 
 
  Active interventiona Control (Placebo unless 
otherwise noted)a 
 
Intervention No. of studies No. with event Total No. No. with event Total No. OR (95% CI) 
All-cause mortality       
Full-dose thrombolysis 16 23 1,010 42 1,006 0.64 (0.37-1.09) 
Low-dose thrombolysis 1 1 61 3 60 0.32 (0.03-3.13) 
Catheter-directed thrombolysis 1 0 30 1 29 0.31 (0.01-7.96) 
Full-dose thrombolysis vs. low-
dose thrombolysis 
4 4 112 7 186 1.04 (0.24-4.41) 
Major bleeding       
Full-dose thrombolysis 16 99 1,010 38 1,006 2.39 (1.44-3.95) 
Low-dose thrombolysis 1 0 61 0 60 Not estimable 
Catheter-directed thrombolysis 1 0 30 0 29 Not estimable 
Full-dose thrombolysis vs. low-
dose thrombolysis 
4 9 112 7 186 2.26 (0.78-6.58) 
Intracranial haemorrhage       
Full-dose thrombolysis 14 
2 
15 983 2 978 3.66 (1.13-11.86) 
Low-dose thrombolysis 1 0 61 0 60 Not estimable 
Catheter-directed thrombolysis 1 0 30 0 29 Not estimable 
Full-dose thrombolysis vs. low-
dose thrombolysis 
3 3 97 0 161 6.85 (0.74-63.24) 
Recurrent VTE       
Full-dose thrombolysis 11 19 945 37 945 0.57 (0.32-1.03) 
Low-dose thrombolysis 1 0 61 3 60 0.13 (0.01-2.64) 
Catheter-directed thrombolysis 1 0 30 0 29 Not estimable 
Full-dose thrombolysis vs. low-
dose thrombolysis 
3 4 97 6 161 1.35 (0.36-5.00) 
 
a Patients also received standard anticoagulation 
 
Abbreviations: OR, odds ratio; CI, confidence interval; VTE, venous thromboembolism.  
 
 
 
